Fierce Biotech: Tenaya tackles genetic heart condition after thorough screening process nails down target

Jul 11, 2022
PDF Version

Writing for Fierce Biotech, reporter Max Bayer summarizes Tenaya’s preclinical study for dilated cardiomyopathy published in July 2022. The study identified the HDAC6 inhibitor as a target for the potential treatment of DCM.

Read More

RSS Feeds
Email Alerts
Contact IR
Print